Literature DB >> 23391197

Discontinuation of rivaroxaban: filling in the gaps.

Matthew R Reynolds.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23391197     DOI： 10.1016/j.jacc.2012.09.056

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  3 in total

1.  Withdrawal of Antithrombotic Agents and the Risk of Stroke.

Authors:  Monica L Wagner; Jane C Khoury; Kathleen Alwell; Eric Rademacher; Daniel Woo; Matthew L Flaherty; Aaron M Anderson; Opeolu Adeoye; Simona Ferioli; Brett M Kissela; Dawn Kleindorfer; Joseph P Broderick
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-01-28       Impact factor: 2.136

2.  Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials.

Authors:  Kengo Ayabe; Shinichi Goto; Shinya Goto
Journal:  J Am Heart Assoc       Date:  2016-02-23       Impact factor: 5.501

3.  Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience.

Authors:  Ajay Agarwal; Amish Patel; Omar Mufti; Yaser Jbara; Ali Abdul Jabbar
Journal:  Cardiol Res       Date:  2014-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.